FDA AdCom backs new asthma rescue treatment from AstraZeneca

9 November 2022

UK pharma major AstraZeneca (LSE: AZN) today reported that the US Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee has voted overwhelmingly to recommend approval of PT027 (albuterol/budesonide) as a new rescue treatment in the USA for people 18 years of age and older, but was not so supportive for younger age groups.

Investor reaction was tepid, with AstraZeneca’s shares up just 1% at 10,744 pence at best, as the company said it is well-placed to transform current asthma emergency treatment approaches.

The PADAC voted 16 to 1 that the data support a favorable benefit risk assessment for the use of PT027 (albuterol/budesonide) for the treatment of asthma in people aged 18 years and older.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK